Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025
Supernus Pharmaceuticals (SUPN) has scheduled its first quarter 2025 financial results announcement for Tuesday, May 6, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET on the same day, featuring President and CEO Jack Khattar and Senior VP and CFO Tim Dec.
The presentation will include Q1 2025 financial and business results, followed by a Q&A session. Investors can access the live webcast through the Events & Presentations section of Supernus' Investor Relations website. Pre-registration is available for participants, who will receive a personalized conference code. A replay will be available on the company's website for 60 days following the live call.
Supernus Pharmaceuticals (SUPN) ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per martedì 6 maggio 2025, dopo la chiusura del mercato. La società terrà una conference call e una webcast alle 16:30 ET dello stesso giorno, con la partecipazione del Presidente e CEO Jack Khattar e del Senior VP e CFO Tim Dec.
La presentazione includerà i risultati finanziari e aziendali del primo trimestre 2025, seguiti da una sessione di domande e risposte. Gli investitori potranno accedere alla diretta streaming tramite la sezione Eventi e Presentazioni del sito web Investor Relations di Supernus. È disponibile la pre-registrazione per i partecipanti, che riceveranno un codice conferenza personalizzato. La registrazione sarà disponibile sul sito della società per 60 giorni dopo la diretta.
Supernus Pharmaceuticals (SUPN) ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el martes 6 de mayo de 2025, después del cierre del mercado. La compañía realizará una conferencia telefónica y una transmisión en vivo a las 4:30 p.m. ET del mismo día, con la participación del Presidente y CEO Jack Khattar y el Vicepresidente Senior y CFO Tim Dec.
La presentación incluirá los resultados financieros y comerciales del primer trimestre de 2025, seguida de una sesión de preguntas y respuestas. Los inversores podrán acceder a la transmisión en vivo a través de la sección de Eventos y Presentaciones del sitio web de Relaciones con Inversores de Supernus. Está disponible el pre-registro para los participantes, quienes recibirán un código personalizado para la conferencia. La repetición estará disponible en el sitio web de la compañía durante 60 días después de la llamada en vivo.
Supernus Pharmaceuticals (SUPN)는 2025년 5월 6일 화요일 장 마감 후 2025년 1분기 재무 실적 발표를 예정하고 있습니다. 회사는 같은 날 오후 4시 30분(동부 시간)에 사장 겸 CEO 잭 카타르와 수석 부사장 겸 CFO 팀 덱이 참석하는 컨퍼런스 콜 및 웹캐스트를 진행할 예정입니다.
발표 내용에는 2025년 1분기 재무 및 사업 실적이 포함되며, 이어서 질의응답 시간이 진행됩니다. 투자자들은 Supernus 투자자 관계 웹사이트의 이벤트 및 발표 섹션을 통해 실시간 웹캐스트에 접속할 수 있습니다. 참가자들은 사전 등록이 가능하며, 개인 맞춤형 컨퍼런스 코드를 받게 됩니다. 생중계 후 60일 동안 회사 웹사이트에서 다시보기 서비스를 이용할 수 있습니다.
Supernus Pharmaceuticals (SUPN) a programmé l’annonce de ses résultats financiers du premier trimestre 2025 pour le mardi 6 mai 2025, après la clôture du marché. La société tiendra une conférence téléphonique et une webdiffusion à 16h30 ET le même jour, avec la participation du Président et CEO Jack Khattar et du Vice-Président Senior et CFO Tim Dec.
La présentation comprendra les résultats financiers et commerciaux du premier trimestre 2025, suivis d’une session de questions-réponses. Les investisseurs pourront accéder à la webdiffusion en direct via la section Événements et Présentations du site des Relations Investisseurs de Supernus. Une préinscription est disponible pour les participants, qui recevront un code personnalisé pour la conférence. Le replay sera accessible sur le site de la société pendant 60 jours après la diffusion en direct.
Supernus Pharmaceuticals (SUPN) hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für Dienstag, den 6. Mai 2025, nach Börsenschluss geplant. Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz und Webcast veranstalten, bei der Präsident und CEO Jack Khattar sowie Senior VP und CFO Tim Dec teilnehmen.
Die Präsentation umfasst die finanziellen und geschäftlichen Ergebnisse des ersten Quartals 2025, gefolgt von einer Fragerunde. Investoren können über den Bereich „Events & Presentations“ auf der Investor-Relations-Website von Supernus auf den Live-Webcast zugreifen. Eine Voranmeldung ist möglich, Teilnehmer erhalten einen persönlichen Konferenzcode. Eine Aufzeichnung steht auf der Firmenwebsite für 60 Tage nach dem Live-Call zur Verfügung.
- None.
- None.
ROCKVILLE, Md., April 23, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the first quarter of 2025 after the market closes on Tuesday, May 6, 2025.
Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to present the first quarter 2025 financial and business results on Tuesday, May 6, 2025 at 4:30 p.m. ET. Following management’s prepared remarks and discussion of business results, the call will be open for questions.
A live webcast will be accessible in the Events & Presentations section of the Company’s Investor Relations website at www.supernus.com/investors.
Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.
Following the live call, a replay will be available on the Company's Investor Relations website at www.supernus.com/investors. The webcast will be available on the Company’s website for 60 days following the live call.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel CNS product candidates including new potential treatments for epilepsy, depression, and other CNS disorders.
For more information, please visit www.supernus.com.
CONTACTS:
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591
or
INVESTOR CONTACT:
Peter Vozzo
ICR Healthcare
(443) 213-0505
peter.vozzo@icrhealthcare.com
FAQ
When will Supernus Pharmaceuticals (SUPN) release Q1 2025 earnings?
How can investors access SUPN's Q1 2025 earnings call?
What time is Supernus Pharmaceuticals' (SUPN) Q1 2025 earnings call?
How long will SUPN's Q1 2025 earnings call replay be available?
